vinorelbine
information and resources from the National Cancer Institute
NCI Thesaurus | vinorelbine
A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. NCI Thesaurus | vinorelbine
A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.
Navelbine
Navelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unreseactable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Navelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Navelbine is indicated in combination with cisplatin.
GlaxoSmithKline Nov 05 2002
Navelbine
Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC).
GlaxoSmithKline Dec 23 1994
|
|
|
|
news articles
ADVENTRX Announces Upcoming Scientific Conference Presentations Mar 28, 2006
Yahoo! News (press release) ...today that it will present preclinical study results for its antiviral compound, Thiovir(TM), and its oncology compound, ANX-530 (vinorelbine emulsion) at ...
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Genetic Engineering News, 2006. -- Sphingosomal vinorelbine targeted to start clinical trials in 2006, and sphingosomal topotecan in 2007. -- Proprietary ...
INEX Releases 2005 Operating Results Mar 30, 2006
CNW Telbec (Communiqués de presse), ...reduced with many of the Company's phase 2 clinical trials for Marqibo and preclinical studies for INX-0125 (sphingosomal vinorelbine), which were ongoing ...
American Journal of Respiratory and Critical Care Medicine Vol 173 ... Mar 28, 2006
AJRCCM (subscription), ...of an adjuvant therapy trial in patients with total resected stage IB or II NSCLC randomized to observation or four cycles of vinorelbine plus cisplatin ...
Hana will license three cancer drugs for $11.5M Mar 17, 2006
San Francisco Business Times, ...to license development and sales rights for the chemotherapy drug candidates Marquibo (sphingosomal vincristine), sphingosomal vinorelbine and sphingosomal ...
Hana Paying Up To $42M For Inex’s Cancer Drugs Mar 17, 2006
BioWorld Online (subscription), The other two drugs in the Inex licensing deal, sphingosomal vinorelbine and sphingosomal topotecan, will enter the clinic this year and next, respectively. ...
Hana Biosciences to license cancer drugs Mar 17, 2006
BusinessWeek ...payments, for global development and commercialization rights to chemotherapy drugs sphingosomal vincristine, sphingosomal vinorelbine, and sphingosomal ...
ADVENTRX Announces 2005 Fourth Quarter and Full Year Financial ... Mar 16, 2006
MSN Money Phase III clinical trial, continued preclinical development of Thiovir and preclinical development of the newly acquired compound, ANX-530 (vinorelbine emulsion ...
Inex Signs LoI To License 3 Cancer Products To Hana Biosciences ... Mar 17, 2006
Trading Markets, Pharmaceuticals Corp. (IEX.TO). The three candidates are namely Marqibo, sphingosomal vinorelbine, and sphingosomal topotecan. Upon closing ...
Inex Pharmaceuticals Licenses Three Targeted Chemotherapy Products ... Mar 17, 2006
Canada NewsWire (press release), INEX has granted Hana a worldwide license to develop and commercialize Marqibo(TM) (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 ...
SD Pharmaceuticals Inc. Reports Positive Efficacy Data on Its Non ... Mar 24, 2006
Genetic Engineering News, ...such as anaphylactic shock, vein irritation and phlebitis associated with the currently marketed formulations; these include vinorelbine, docetaxel, paclitaxel ...
Novacea Appoints Amar Singh as Chief Commercialization Officer Mar 15, 2006
Market Wire (press release) The Company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, vinorelbine oral, which ...
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... Mar 6, 2006
Cancer Consultants (press release), Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU ...
Short Course of Herceptin® in Patients with Breast Cancer Dec 9, 2005
Cancer Consultants (press release), In breast cancer patients treated with docetaxel or vinorelbine followed by FEC (5-fluorouracil, epirubicin, cyclophosphamide), a nine-week course of Herceptin ...
ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome Dec 7, 2005
Biotech Intelligence (press release), ...with the US Food and Drug Administration (FDA) regarding the proposed 505(b)(2) New Drug Application (NDA) regulatory plan for ANX-530 (vinorelbine emulsion). ...
Treatment of Breast Cancer with Herceptin for Nine Weeks Dec 10, 2005
MedIndia, The women included in the study received docetaxel or vinorelbine and then FEC (5-fluorouracil, epirubicin, cyclophosphamide).Those whose HER-2 protein were ...
SD Pharmaceuticals Completes Studies on the Feasibility of a Novel ... Dec 14, 2005
Genetic Engineering News, ...as anaphylactic shock, vein irritation and phlebitis associated with the currently marketed formulations; these include Vinorelbine, Paclitaxel, Clarithromycin ...
Trastuzumab Used as First Line Therapy in Women Whose Cancer Has ... Dec 12, 2005
DG News ...real-life" study. Such agents included paclitaxel and docetaxel, vinorelbine, capecitabine cisplatin and doxorubicin. lead author ...
Prostate Cancer: New choice for hormone refractory patients Dec 8, 2005
PharmaLive.com (press release), ...s recent co-development with Pierre Fabre means that Novacea is likely to investigate the use of its drug DN-101 with oral Navelbine (vinorelbine) for HRPC. ...
INEX Appoints President & CEO and Updates Reorganization Timetable Dec 6, 2005
PR Newswire (press release), ...focus on extracting value via partnering from its late-stage Targeted Chemotherapy platform including Marqibo(TM), INX-0125 (sphingosomal vinorelbine) and INX ...
Induction Chemotherapy and Concomitant Chemoradiotherapy Promising ... Dec 6, 2005
Cancer Consultants (press release), IIIB NSCLC. The median age was 59 years. Induction chemotherapy involved three cycles of gemcitabine and vinorelbine. This was followed ...
Induction Chemotherapy Promising in Stage III Non-Small Cell Lung ... Dec 2, 2005
Cancer Consultants (press release), NSCLC. The median age of the patients was 59 years. Induction chemotherapy involved three cycles of gemcitabine and vinorelbine. This ...
(Euronext Paris) - Transgene : Clinical Pipeline Update Nov 29, 2005
Euronext, II trial of TG4010 were presented at ASCO in May 2005 showing that the combination of TG4010 with chemotherapy (cisplatin and vinorelbine) compared favourably ...
Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... Nov 20, 2005
Xagena.it, ...with GLA sensitizes breast cancer cells to some chemotherapeutic drugs, such as Paclitaxel ( Taxol ), Docetaxel ( Taxotere ) and Vinorelbine ( Navelbine ). ...
|
|
